130 related articles for article (PubMed ID: 22734222)
1. [Anti-adenovirus neutralizing antibodies and Gag-specific cellular immune responses in Macaca fascicularis immunized with Ad5-HIVgag].
Li Y; Yang L; Yang L; Chen DY; Feng X; Yu SQ; Li ZL; Zeng Y
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2011 Dec; 25(6):413-5. PubMed ID: 22734222
[TBL] [Abstract][Full Text] [Related]
2. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.
Liang X; Casimiro DR; Schleif WA; Wang F; Davies ME; Zhang ZQ; Fu TM; Finnefrock AC; Handt L; Citron MP; Heidecker G; Tang A; Chen M; Wilson KA; Gabryelski L; McElhaugh M; Carella A; Moyer C; Huang L; Vitelli S; Patel D; Lin J; Emini EA; Shiver JW
J Virol; 2005 Oct; 79(19):12321-31. PubMed ID: 16160159
[TBL] [Abstract][Full Text] [Related]
3. Heterologous HIV-based lentiviral/adenoviral vectors immunizations result in enhanced HIV-specific immunity.
Asefa B; Korokhov N; Lemiale F
Vaccine; 2010 Apr; 28(20):3617-24. PubMed ID: 20051277
[TBL] [Abstract][Full Text] [Related]
4. [Study on vector-specific and foreign gene-specific immune responses induced by rAd5 and rAAV2/1 vaccines].
Yang L; Li Y; Yang L; Zhang LF; Feng X; Yu SQ; Chen DY; Li ZL; Zeng Y
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2011 Dec; 25(6):431-3. PubMed ID: 22734227
[TBL] [Abstract][Full Text] [Related]
5. [Immune responses in rhesus induced by recombinant adenovirus Ad-LMP2].
Wang Z; Zhou L; Wu XB; Lu MJ; Xuan YX; Zuo JM; Li F; Wang Q; Ye SQ; Zeng Y
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2006 Jun; 20(2):63-5. PubMed ID: 16816867
[TBL] [Abstract][Full Text] [Related]
6. Vaccination of mice with replication-defective human immunodeficiency virus induces cellular and humoral immunity and protects against vaccinia virus-gag challenge.
Baliga CS; van Maanen M; Chastain M; Sutton RE
Mol Ther; 2006 Sep; 14(3):432-41. PubMed ID: 16713742
[TBL] [Abstract][Full Text] [Related]
7. Novel Adenovirus type 5 vaccine platform induces cellular immunity against HIV-1 Gag, Pol, Nef despite the presence of Ad5 immunity.
Gabitzsch ES; Xu Y; Yoshida LH; Balint J; Amalfitano A; Jones FR
Vaccine; 2009 Oct; 27(46):6394-8. PubMed ID: 19559110
[TBL] [Abstract][Full Text] [Related]
8. An HIV-based lentiviral vector as HIV vaccine candidate: Immunogenic characterization.
Lemiale F; Asefa B; Ye D; Chen C; Korokhov N; Humeau L
Vaccine; 2010 Feb; 28(8):1952-61. PubMed ID: 20188251
[TBL] [Abstract][Full Text] [Related]
9. Adenovirus vectored vaccines.
Natuk RJ; Davis AR; Chanda PK; Lubeck MD; Chengalvala M; Murthy SC; Wade MS; Dheer SK; Bhat BM; Murthy KK
Dev Biol Stand; 1994; 82():71-7. PubMed ID: 7958485
[TBL] [Abstract][Full Text] [Related]
10. A combination HIV vaccine based on Tat and Env proteins was immunogenic and protected macaques from mucosal SHIV challenge in a pilot study.
Ferrantelli F; Maggiorella MT; Schiavoni I; Sernicola L; Olivieri E; Farcomeni S; Pavone-Cossut MR; Moretti S; Belli R; Collacchi B; Srivastava IK; Titti F; Cafaro A; Barnett SW; Ensoli B
Vaccine; 2011 Apr; 29(16):2918-32. PubMed ID: 21338681
[TBL] [Abstract][Full Text] [Related]
11. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.
Shiver JW; Fu TM; Chen L; Casimiro DR; Davies ME; Evans RK; Zhang ZQ; Simon AJ; Trigona WL; Dubey SA; Huang L; Harris VA; Long RS; Liang X; Handt L; Schleif WA; Zhu L; Freed DC; Persaud NV; Guan L; Punt KS; Tang A; Chen M; Wilson KA; Collins KB; Heidecker GJ; Fernandez VR; Perry HC; Joyce JG; Grimm KM; Cook JC; Keller PM; Kresock DS; Mach H; Troutman RD; Isopi LA; Williams DM; Xu Z; Bohannon KE; Volkin DB; Montefiori DC; Miura A; Krivulka GR; Lifton MA; Kuroda MJ; Schmitz JE; Letvin NL; Caulfield MJ; Bett AJ; Youil R; Kaslow DC; Emini EA
Nature; 2002 Jan; 415(6869):331-5. PubMed ID: 11797011
[TBL] [Abstract][Full Text] [Related]
12. Designed recombinant adenovirus type 5 vector induced envelope-specific CD8(+) cytotoxic T lymphocytes and cross-reactive neutralizing antibodies against human immunodeficiency virus type 1.
Ura T; Yoshida A; Xin KQ; Yoshizaki S; Yashima S; Abe S; Mizuguchi H; Okuda K
J Gene Med; 2009 Feb; 11(2):139-49. PubMed ID: 19065543
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of recombinant adenovirus-human immunodeficiency virus vaccines in chimpanzees following intranasal administration.
Lubeck MD; Natuk RJ; Chengalvala M; Chanda PK; Murthy KK; Murthy S; Mizutani S; Lee SG; Wade MS; Bhat BM
AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1443-9. PubMed ID: 7888199
[TBL] [Abstract][Full Text] [Related]
14. A preliminary and comparative evaluation of a novel Ad5 [E1-, E2b-] recombinant-based vaccine used to induce cell mediated immune responses.
Gabitzsch ES; Xu Y; Yoshida LH; Balint J; Gayle RB; Amalfitano A; Jones FR
Immunol Lett; 2009 Jan; 122(1):44-51. PubMed ID: 19073216
[TBL] [Abstract][Full Text] [Related]
15. Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins.
Mascola JR; Sambor A; Beaudry K; Santra S; Welcher B; Louder MK; Vancott TC; Huang Y; Chakrabarti BK; Kong WP; Yang ZY; Xu L; Montefiori DC; Nabel GJ; Letvin NL
J Virol; 2005 Jan; 79(2):771-9. PubMed ID: 15613305
[TBL] [Abstract][Full Text] [Related]
16. Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors.
Casimiro DR; Bett AJ; Fu TM; Davies ME; Tang A; Wilson KA; Chen M; Long R; McKelvey T; Chastain M; Gurunathan S; Tartaglia J; Emini EA; Shiver J
J Virol; 2004 Oct; 78(20):11434-8. PubMed ID: 15452269
[TBL] [Abstract][Full Text] [Related]
17. Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector.
Juillard V; Villefroy P; Godfrin D; Pavirani A; Venet A; Guillet JG
Eur J Immunol; 1995 Dec; 25(12):3467-73. PubMed ID: 8566039
[TBL] [Abstract][Full Text] [Related]
18. Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunization.
Cheng C; Gall JG; Nason M; King CR; Koup RA; Roederer M; McElrath MJ; Morgan CA; Churchyard G; Baden LR; Duerr AC; Keefer MC; Graham BS; Nabel GJ
J Virol; 2010 Jan; 84(1):630-8. PubMed ID: 19846512
[TBL] [Abstract][Full Text] [Related]
19. [Immunogenicity of a chimeric adenovirus type 5 vector with type 35 fiber containing HIV-1 gag in mice].
Liu XL; Yu SQ; Feng X; Wang XL; Liu HM; Zhang XM; Li HX; Zhou L; Li ZL; Zheng Y
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2007 Mar; 21(1):5-7. PubMed ID: 17429520
[TBL] [Abstract][Full Text] [Related]
20. [Comparison of the immnunogenicity of rAAV2/1 and rAd5 rad5 expressing HIV-1 gag].
Yu SQ; Feng X; Liu HM; Yang HR; Li HX; Zeng Y
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2009 Dec; 23(6):421-3. PubMed ID: 20718344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
